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An Asian Indian Woman with Wolfram Syndrome
on Insulin Pump: Successful Pregnancy and Beyond
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Abstract

Wolfram syndrome (WS), or DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness), is a
rare autosomal recessive neurodegenerative disorder with a median life expectancy of 30 years and occurs in one
in 770,000 live births. To date only five successful pregnancies have been reported among WS subjects worldwide.
Here we describe the sixth report of successful pregnancy in a WS patient and the first from India. The subject is
still on an insulin pump, now 31 years old and doing well. She developed diabetes at 5 years of age, optic atrophy
at 14 years, and diabetes insipidus at 25 years and had a successful delivery in 2007 while on an insulin pump.
Sequencing of exonic regions of the WFS1 gene showed five changes, two of which were pathogenic (exon 8).
Magnetic resonance imaging of brain showed generalized neurodegenerative changes. The benefits of continuous
subcutaneous insulin infusion and that of tight metabolic control in prevention of abortions and fetal malformations in diabetes associated with pregnancy are well documented. The impression of probable pleiotropic
action of insulin pumps over and above that of glycemic reduction is gaining momentum. Recent evidence
supports use of insulin pumps in alleviating neuropathic pain in diabetes, probably by virtue of its action in
minimizing mean amplitude of glycemic excursions not possible with conventional insulin shots. WS is a progressive neurodegenerative disorder, which will probably help us in understanding the positive impact of continuous subcutaneous insulin infusion in prolonging the life span and retarding neuronal damage in WS.

Introduction

Case Report

W

A 27-year-old woman enrolled with us in August 2005 for
comprehensive management of her childhood-onset diabetes
mellitus. She was diagnosed as having diabetes mellitus by the
age of 5 years. This was followed by development of progressive defective vision in both eyes since the age of 14 years,
and she was diagnosed as having primary bilateral optic atrophy. At the age of 25 years, she had one admission for an
acute psychosis and attempted suicide, after which she fully
recovered. During this period of hospitalization, she developed severe electrolyte imbalances and was evaluated in detail. A diagnosis of diabetes insipidus was made, and she was
started on desmopressin. She attained menarche at the age of
14 years and has regular menstrual cycles since then.
Her family history is significant in that she was born of a
consanguineous marriage and has a brother who also has the
same spectrum of disorders.
During the first visit in August 2005, her hemoglobin A1c
(HbA1c) level was 8.3%. Other laboratory values were within

olfram syndrome (WS) is a rare progressive neurodegenerative disorder, with a predominantly autosomal recessive inheritance pattern. The acronym of
DIDMOAD constitutes the most common features of the
syndrome—diabetes insipidus, diabetes mellitus, optic atrophy, and deafness. Apart from these, patients with WS may
develop further neurological, urological, and psychiatric features. Previously only five cases of successful pregnancy in
WS have been reported worldwide.1
Here we report the sixth case (and the first from India) of
successful pregnancy in such a patient. She was started on an
insulin pump, considering that her diabetes was poorly controlled, and that she had long-term plans to marry and conceive. She is still on continuous subcutaneous insulin infusion
(CSII), and the child is now 3 years old. Although the WSinduced neurodegenerative changes are gradually progressing, the prolonged longevity and maintenance of improved
quality of life are compelling evidence in favor of CSII.
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acceptable limits. Initial ophthalmologic evaluation confirmed a defective vision, with a visual acuity of 6/60 in both
eyes. Fundus examination showed features suggestive of
primary bilateral optic atrophy and early posterior polar
cataract. Color vision was also significantly impaired.
At our center, she was initially started on a basal–bolus
regimen consisting of once-daily insulin glargine and three
times-daily premeal insulin aspart. She was put on regular
telephone follow-up. Despite modifications in diet, exercise,
and medications, she had wide fluctuations in her blood sugar
levels. She underwent continuous glucose monitoring
(CGMS System Gold, Medtronic, Northridge, CA) for 3
days. Considering the wide excursions in her glycemic levels,
her future plans to conceive, higher socioeconomic status, selflearning skills, and motivation, we started her on an insulin
pump.2 After the insulin pump was set up, her HbA1c was
maintained between 5.2% and 5.9%. She was physically and
mentally in perfect health except for bilateral diminution of
vision.
She got married and became pregnant in December 2006.
Throughout the course of pregnancy diabetes mellitus was
aggressively managed. In our center we make use of the
Diabetes Tele Management System (DTMS)3 wherein four to
11 blood glucose measurements are done at home with a
glucometer and dosages are modified through telephone or
internet. Correction boluses of aspart insulin were administered through the pump whenever self-monitored glucose
values were above 125 mg%, thus maintaining an A1c below
6% throughout the course of her pregnancy (Table 1). The
dose of desmopressin did not require any alteration as her
diabetes insipidus remained stable.
Since conception, she was under regular care of the obstetrician. All her physical and laboratory parameters were reassuring during this period. She was admitted to the hospital
in the next to last month of her pregnancy. This enabled strict
monitoring of her homeostasis and for due adjustments to be
made. A cesarean section was done, and a healthy male baby
weighing 3.10 kg was delivered. Postoperatively, hourly
glucose monitoring was done for a 24-h period, and the insulin dose was adjusted accordingly. She had an uneventful
postpartum period. The baby was also evaluated in detail,
and like in previously reported cases, the baby was in normal
health.

The patient was discharged with advice to undergo regular
postnatal checkups and follow-up with us for the management of her blood glucose levels. Two weeks into the postpartum period, she visited the center for her routine checkup.
A magnetic resonance imaging (MRI) scan taken during this
period showed features suggestive of generalized atrophy of
cortex, brainstem, and cerebellum. Ultrasound evaluation of
her genitourinary system revealed bilateral hyrdronephrosis
and hydroureters. Ophthalmologic findings suggested further deterioration of vision (R 5/60 and L 4/60).
Routine evaluation done in early March 2010 gave an
HbA1c of 7.8% and normal liver function tests (aspartate
aminotransaminase, 28 IU/L; alanine aminotransaminase,
30 IU/L), kidney function tests (urea, 16 mg/dL; creatinine,
0.7 mg/dL), and total cholesterol (116 mg/dL). The electrolyte
analysis showed a serum sodium of 134.1 mEq/L and serum
potassium of 3.9 mEq/L. Furthermore, the serum osmolality
showed a normal value of 288 mOsm/kg, and the 24-h urine
total volume was 2,200 mL. The nerve conduction velocity
report on motor nerve conduction showed normal distal latency, whereas the sensory conduction study showed bilateral
distal peak latency prolonged from both median nerves. The
MRI report showed diffuse cerebral and cerebellar atrophy
associated with mild atrophy of the pons and midbrain.
Fundus examination showed her best corrected visual acuity
as 3/60 in both eyes, and her near vision was N12 with a 5.0D
sphere. Her intraocular pressure was 18 in both eyes, and
there were no diabetic retinopathy changes. The echocardiogram showed mild mitral valve prolapse and no mitral
regurgitation.
Genetic analysis for WS was performed by polymerase
chain reaction amplification and direct sequencing by Bioserve Biotechnologies India Pvt. Ltd. (Hyderabad, India) (licensed by the World Health Organization to perform
bioassays).
The methodology used for the gene sequencing was as
follows: DNA was isolated from whole blood and was
quantitated and diluted to a concentration of 100 ng/mL. The
diluted DNA was used in the polymerase chain reaction with
the specified primers in the supplied literature. The polymerase chain reaction products were gel-eluted and subjected
to sequencing; the primers used for sequencing were the same
primers used for amplification.

Table 1. Blood Glucose Levels and Annual Hemoglobin A1c Values over a Period
of 5 Years, Before and After Being on Continuous Subcutaneous Insulin Infusion
Value (mg/dL)
Parameter

2005 (before initiation
of insulin pump therapy)

2006 (after initiation
of insulin pump therapy)

2007

2008

2009

2010

287
159
272
198
53
397
192
8.3%

92
117
114
124
119
132
118
5.8%

106
134
102
159
116
142
121
6.2%

121
129
113
214
156
184
140
7.1%

89
103
106
116
112
137
123
6.9%

102
152
149
127
176
145
142
7.2%

Blood sugar
Fasting
Pre-breakfast
Post-breakfast
Pre-lunch
Post-lunch
Pre-dinner
Post-dinner
HbA1c
HbA1c, hemoglobin A1c.
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FIG. 1. Sequencing trace data of T insertion and G>A in exon 8 of the Wolfram syndrome gene WFS1. Fwd, forward; Rev,
reverse. Color version available online at www.liebertonline.com/dia
Sequencing of the exonic regions of WFS1 gene showed five
changes with the sample: (1) G>T polymorphism in the 50
flanking region of exon 1; (2) G>A polymorphism in the
flanking region of exon 6; (3) G>A mutation in exon 8; (4) T
insertion mutation in exon 8; and (5) C>T polymorphism in
exon 8.
Based on the trace data all these are homozygous changes.
The genetic analysis of exon 8 in the WFS1 gene of this patient
showed two likely disease-causing homozygous mutations: T
insertion causes truncation (711 AA instead of 891) (Fig. 1),
and G>A exon 8 is missense V>I.
Discussion
WS is a progressive neurodegenerative disorder that constitutes an association of diabetes mellitus and optic atrophy.
It was first described by Wolfram in 1938 in four siblings as
noted by Sunder et al.4 It is sometimes called DIDMOAD, the
acronym for the major manifestations of the disorder, namely,
diabetes insipidus, diabetes mellitus, optic atrophy, and
deafness. The prevalence of WS according to studies conducted in the United Kingdom was 1:770,000, whereas independent studies in North America had shown a rate of
1:100,000.5 The pattern of inheritance is mostly autosomal
recessive, but the influence that certain variations in the mitochondrial genome may exert, to result in the increased

predisposition to this disorder, has also been suggested. The
gene responsible for the syndrome, identified in 1998, has
been linked to the short arm of chromosome 4p. It has been
termed Wolframin gene or WFS1. Mutations in WFS1 can be
found in the majority of the patients with this disorder, although most of the mutations are new and vary with families.5 WFS1 spans 33.4 kb of genomic DNA and includes eight
exons: exon 1 is noncoding, exons 2–7 are coding, and exon 8
is 2.6 kb long. WFS1 mRNA encodes an 890-amino acid
polypeptide with nine putative transmembrane domains and
a 100-kDa molecular mass. Wolframin protein is an endoglycosidase H–sensitive membrane glycoprotein that localizes in the endoplasmic reticulum. In the endoplasmic
reticulum, it regulates membrane trafficking and protein
processing and has a crucial role in cell death through the
apoptotic pathway.6 The mechanisms responsible for the
phenotype of carbohydrate intolerance and loss of pancreatic
b cells in this disorder may be attributed to lack of expression
of WFS1 in b cells, resulting in the diabetes mellitus phenotype. The b cell death occurs by an accelerated process of
apoptosis, and lack of WFS1 is associated with dilated endoplasmic reticulum and increased markers of endoplasmic reticulum stress, significantly contributing to the reduction in
b cell survival.7
The diagnosis of WS is essentially clinical and requires the
presence of only diabetes mellitus and optic atrophy by the

784
age of 15 years (it has a positive predictive value of 83% and a
negative predictive value of 1%). The addition of other features does not augment the diagnostic precision by very
much. In the absence of a specific diagnostic marker, the
presence of diabetes mellitus and optic atrophy can be considered the diagnostic criteria.8 The disorder is usually found
in children born of consanguineous marriages, like in our
patient. However, a history of consanguinity is not essential
for the occurrence of this syndrome. The prevalence and age
of onset of other components like diabetes insipidus, deafness,
and other clinical features are variable. Previous studies
showed that although diabetes mellitus and optic atrophy had
a 100% prevalence, the occurrence of the other abnormalities
varies.8 Optic atrophy is the most common ophthalmologic
finding in these patients. Additional features include mainly
color blindness and cataract.9 The findings in our patient
support this. MRI scan of the brain showed findings suggestive of generalized atrophy of cortex, brainstem, and cerebellum. This is in concurrence with the MRI findings in the
previously studied cases of WS.5 In comparison with the
previous MRI scans of the patient, the current MRI scan revealed further progression of the neurological findings. Ultrasound of the genitourinary system showed bilateral
hydronephrosis and hydroureters. Dilatation of the urinary
tract could be attributed to the volume overload as a result of
diabetes insipidus.8 Pure tone audiometry was normal, and
deafness was ruled out. However, deafness had a prevalence
of only 62% in studies conducted earlier, and its absence does
not alter the diagnosis. Acute psychotic episodes and attempts
at suicide, as in our patient, are well documented in previous
studies. Other possible manifestations may include paranoid
delusions, progressive dementia, depression, hallucinations,
and violent behavior.10 Patients with this disorder have a reduced lifespan, with the median age of death being 30 years.
Common causes of mortality are the complications of diabetes
mellitus, respiratory failure, recurrent infections, status epilepticus, and suicide due to endogenous depression.8
Pregnancy in WS has been a rarity. Only five cases have
been reported worldwide. Successful pregnancy in WS has
not been reported from India so far. It is rare because of the
menstrual irregularities and abnormal functioning of the hypothalamo-pituitary-ovarian axis.8 The diabetes insipidus
seemed to have mounted a stiff challenge to efficient management of the antenatal and postpartum periods in previously reported cases.1 Our patient has been on regular
desmopressin since the age of 25 years, and her diabetes insipidus remained stable during the antenatal period, ensured
by close follow-up of her electrolyte status and osmolality. For
better control of her blood glucose levels, she was initially put
on multiple daily injections of insulin. Despite regular modifications in the insulin dosages, dietary regulations, and exercise, her HbA1c never came below 7%. During this period,
she was visibly enthusiastic in regular self-monitoring of
blood glucose and administering extra boluses of rapid-acting
insulin based on the sugar values. Her willingness to monitor
blood sugar and self-management skills were encouraging
signs for family members and the team associated with Diabetes Tele Management System (DTMS). At this juncture,
she appeared to be an appropriate candidate for pump therapy, the option of using an insulin pump was discussed, and
she seemed to be receptive to this modality.11 Under the
comprehensive care level, as recommended by the Interna-
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tional Diabetes Federation, for patients with pregnancy and
antecedent diabetes, insulin delivery might be optimized by
the use of CSII.12 She belonged to a higher socioeconomic
status, was a postgraduate by education, and was very well
acquainted with the use of electronic media, gadgets, and
computers. Moreover, the center has adequately trained and
certified pump trainers to back the dedicated 24-h helpline of
the DTMS. The blood sugar during the antenatal period was
also efficiently managed through CSII, and it considerably
enhanced her quality of life and overall well-being. Considering the unstable nature of the blood glucose levels, its
wide excursions, and the detrimental effects it could pose for
the growing fetus, we would like to emphasize the importance
of using an insulin pump for the management of diabetes mellitus during pregnancy.13 Her husband and relations at home
were helping her throughout with her insulin pump, and this
supportive mechanism ensured continuing success with CSII.
In a real-life study published recently, 46 type 2 diabetes
subjects using multiple daily injections when switched over to
CSII for 6 months reported not only significant reduction in
HbA1c levels but also improvement in quality of life. After 6
months of CSII, 83% of subjects noted an improvement in
sexual function as opposed to when they were using multiple
daily injections. With respect to peripheral neuropathic pain,
87% of subjects reported that they experienced significant
reduction in pain after initiation of CSII.14 This probably indicates the influence of CSII on mean amplitude of glycemic
excursions, an action not to be expected with conventional
insulin shots.
Four years postpartum, she is still on CSII. Because WS is a
progressive neurodegenerative disorder, this case report will
probably help us understand the positive impact of CSII in
prolonging the life span and retarding neuronal damage in WS.
Conclusions
We propose that in any case of childhood-onset diabetes
mellitus with associated optic atrophy, before the age of 15
years, the possibility of WS should be considered. Females
with WS can give birth to healthy babies provided the diabetes mellitus, diabetes insipidus, and associated disorders
are intensively monitored and aggressively managed. The
successful outcome with insulin pump therapy over a 5-year
period in WS provides an opportunity to understand the
benefits of CSII in retarding the progression of neurodegenerative changes and possibly longevity beyond the usual
glycemic control.
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